ADX-629 is under clinical development by Aldeyra Therapeutics and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADX-629’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADX-629 is under development for the treatment of non-alcoholic steatohepatitis (NASH), plaque psoriasis, atopic (allergic) asthma, acute alcoholic hepatitis, inflammatory bowel disease (IBD), cytokine storm, ethanol toxicity, chronic cough, minimal change disease, nephrotic syndrome, atopic dermatitis and Sjogren-Larsson syndrome and COVID-19. The drug candidate is RASP (Reactive Aldehydes Species-Pro-inflammatory) inhibitor, administered through oral route. It is an analog of reproxalap. It acts by targeting aldehyde load.
Aldeyra Therapeutics overview
Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of ADX-629’s drug-specific PTSR and LoA scores, buy the report here.